Reduced-intensity conditioned allogeneic SCT in adults with AML

Bone Marrow Transplantation
R Reshef, D L Porter

Abstract

AML is currently the most common indication for reduced-intensity conditioned (RIC) allo-SCT. Reduced-intensity regimens allow a potent GVL response to occur with minimized treatment-related toxicity in patients of older age or with comorbidities that preclude the use of myeloablative conditioning. Whether RIC SCT is appropriate for younger and more standard risk patients is not well defined and the field is changing rapidly; a prospective randomized trial of myeloablative vs RIC (BMT-CTN 0901) was recently closed when early results indicated better outcomes for myeloablative regimens. However, detailed results are not available, and all patients in that study were eligible for myeloablative conditioning. RIC transplants will likely remain the standard of care as many patients with AML are not eligible for myeloablative conditioning. Recent publication of mature results from retrospective and prospective cohorts provide contemporary efficacy and toxicity data for these attenuated regimens. In addition, recent studies explore the use of alternative donors, introduce regimens that attempt to reduce toxicity without reducing intensity, and identify predictive factors that pave the way to personalized approaches. These studies pain...Continue Reading

References

May 10, 1979·The New England Journal of Medicine·P L WeidenR Storb
Jan 13, 1994·The New England Journal of Medicine·D L PorterJ H Antin
Feb 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R H CollinsJ Nemunaitis
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D L PorterJ H Antin
Jul 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M MichalletJ M Boiron
Oct 11, 2002·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Christian JunghanssRainer Storb
Oct 18, 2002·Blood·Mohamad MohtyUNKNOWN Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)
Mar 3, 2004·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Daniel R CourielRichard Champlin
Feb 1, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Raymond WongSergio Giralt
Mar 9, 2005·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Chirag R ParikhBrenda M Sandmaier
Mar 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Frédéric BaronRainer Storb
Jul 13, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Koen van BesienW Stock
Sep 30, 2005·The New England Journal of Medicine·Robert LowskySamuel Strober
Jan 18, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David A RizzieriNelson J Chao
Mar 27, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Betul OranMarcos de Lima
Jun 21, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Sergio GiraltDaniel Weisdorf
Aug 29, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mohamed L SorrorRainer Storb

❮ Previous
Next ❯

Citations

Sep 10, 2015·Blood·Christoph SchmidUNKNOWN Acute Leukemia Working Party of the European Group of Blood and Bone Marrow Transplantation
Oct 27, 2016·Experimental Hematology·Adam Widman, Ran Reshef
Oct 22, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Hassan SibaiDennis Dong Hwan Kim
Nov 27, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Orly R KleinHeather J Symons
May 29, 2018·Cancer·Martha Arellano, Jennifer Wilkinson Carlisle
Apr 27, 2018·Expert Opinion on Pharmacotherapy·Laura C MichaelisRoland B Walter
Dec 28, 2019·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Peter Westervelt
Sep 29, 2019·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Takaaki KonumaUNKNOWN Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation
May 13, 2021·Health Science Reports·Mohammad RafieeMohammad Hossein Mohammadi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.